Literature DB >> 20471331

Year-to-year changes in lung function in individuals with cystic fibrosis.

Theodore G Liou1, Eric P Elkin, David J Pasta, Joan R Jacobs, Michael W Konstan, Wayne J Morgan, Jeffrey S Wagener.   

Abstract

BACKGROUND: We examined the year-to-year change in FEV(1) for individuals and the overall cystic fibrosis population to better understand how individual trends may differ from population trends.
METHODS: We calculated individual yearly changes using the largest annual FEV(1) percent predicted (FEV(1)%) measurement in 20,644 patients (6-45years old) included in the Epidemiologic Study of Cystic Fibrosis. We calculated yearly population changes using age-specific medians.
RESULTS: FEV(1)% predicted decreased 1-3 points per year for individuals, with maximal decreases in 14-15year olds. Population changes agreed with individual changes up to age 15; however after age 30, yearly population change approximated zero while individual FEV(1)% predicted decreases were 1-2 points per year.
CONCLUSIONS: Adolescents have the greatest FEV(1)% predicted decreases; however, loss of FEV(1) is a persistent risk in 6-45year old CF patients. Recognizing individual year-to-year changes may improve patient-specific care and may suggest new methods for measuring program quality. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20471331      PMCID: PMC4102928          DOI: 10.1016/j.jcf.2010.04.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  30 in total

1.  Respiratory status in dairy farmers in France; cross sectional and longitudinal analyses.

Authors:  H Chaudemanche; E Monnet; V Westeel; D Pernet; A Dubiez; C Perrin; J-J Laplante; A Depierre; J-C Dalphin
Journal:  Occup Environ Med       Date:  2003-11       Impact factor: 4.402

2.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

3.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

4.  Association of cytokine gene polymorphisms with rate of decline in lung function.

Authors:  Berran Yucesoy; Margaret Kurzius-Spencer; Victor J Johnson; Kara Fluharty; Michael L Kashon; Stefano Guerra; Michael I Luster; Jefferey L Burgess
Journal:  J Occup Environ Med       Date:  2008-06       Impact factor: 2.162

5.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

6.  Disease-specific reference equations for lung function in patients with cystic fibrosis.

Authors:  Michal Kulich; Margaret Rosenfeld; Jonathan Campbell; Richard Kronmal; Ron L Gibson; Christopher H Goss; Bonnie Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2005-06-23       Impact factor: 21.405

7.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis.

Authors:  M Corey; L Edwards; H Levison; M Knowles
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

8.  Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokers and smokers in Busselton, Western Australia.

Authors:  J K Peat; A J Woolcock; K Cullen
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

9.  Lung function decline in cystic fibrosis patients and timing for lung transplantation referral.

Authors:  Daniel B Rosenbluth; Kevin Wilson; Thomas Ferkol; Daniel P Schuster
Journal:  Chest       Date:  2004-08       Impact factor: 9.410

10.  Factors influencing outcomes in cystic fibrosis: a center-based analysis.

Authors:  Charles Johnson; Steven M Butler; Michael W Konstan; Wayne Morgan; Mary Ellen B Wohl
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

View more
  33 in total

1.  Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis.

Authors:  Jacoba Johanna Louw; Jaan Toelen; Marijke Proesmans; François Vermeulen; Jaak Billen; Kris de Boeck
Journal:  Eur J Pediatr       Date:  2011-06-01       Impact factor: 3.183

2.  The Epithelial Sodium Channel Is a Modifier of the Long-Term Nonprogressive Phenotype Associated with F508del CFTR Mutations.

Authors:  Pankaj B Agrawal; Ruobing Wang; Hongmei Lisa Li; Klaus Schmitz-Abe; Chantelle Simone-Roach; Jingxin Chen; Jiahai Shi; Tin Louie; Shaohu Sheng; Meghan C Towne; Christine F Brainson; Michael A Matthay; Carla F Kim; Michael Bamshad; Mary J Emond; Norma P Gerard; Thomas R Kleyman; Craig Gerard
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

3.  Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.

Authors:  Rhonda D VanDyke; Gary L McPhail; Bin Huang; Matthew C Fenchel; Raouf S Amin; Adam C Carle; Barb A Chini; Michael Seid
Journal:  Ann Am Thorac Soc       Date:  2013-06

4.  Lung function decline from adolescence to young adulthood in cystic fibrosis.

Authors:  Stacy L Vandenbranden; Ann McMullen; Michael S Schechter; David J Pasta; Rory L Michaelis; Michael W Konstan; Jeffrey S Wagener; Wayne J Morgan; Susanna A McColley
Journal:  Pediatr Pulmonol       Date:  2011-08-24

5.  Early Detection of Rapid Cystic Fibrosis Disease Progression Tailored to Point of Care: A Proof-of-Principle Study.

Authors:  Rhonda Szczesniak; Cole Brokamp; Weiji Su; Gary L McPhail; John Pestian; John P Clancy
Journal:  Health Innov Point Care Conf       Date:  2017-12-21

Review 6.  Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.

Authors:  Rhonda Szczesniak; Sonya L Heltshe; Sanja Stanojevic; Nicole Mayer-Hamblett
Journal:  J Cyst Fibros       Date:  2017-01-20       Impact factor: 5.482

7.  Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.

Authors:  Carlos E Milla; Felix Ratjen; Gautham Marigowda; Fang Liu; David Waltz; Margaret Rosenfeld
Journal:  Am J Respir Crit Care Med       Date:  2017-04-01       Impact factor: 21.405

8.  Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.

Authors:  Rhonda D Szczesniak; Dan Li; Weiji Su; Cole Brokamp; John Pestian; Michael Seid; John P Clancy
Journal:  Am J Respir Crit Care Med       Date:  2017-08-15       Impact factor: 21.405

9.  Is adolescents' religious coping with cystic fibrosis associated with the rate of decline in pulmonary function?-A preliminary study.

Authors:  Daniel H Grossoehme; Rhonda Szczesniak; Gary L McPhail; Michael Seid
Journal:  J Health Care Chaplain       Date:  2013

10.  Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.

Authors:  Laura A McCauley; William Thomas; Theresa A Laguna; Warren E Regelmann; Antoinette Moran; Lynda E Polgreen
Journal:  Ann Am Thorac Soc       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.